logo-loader

IQ-AI's Imaging Biometrics developing technology that could 'revolutionise brain tumour imaging'

Published: 15:12 15 Jul 2020 BST

Michael Schmainda, co-founder and CEO of IQ-AI Limited's (LON:IQAI) subsidiary Imaging Biometrics tells Proactive London's Andrew Scott they're developing a technology that could revolutionise the detection and treatment of brain tumours. IB CAD has been created to pick up cancer cells before they are visible on standard imaging. It does this by combining multi-parameter magnetic resonance data and artificial intelligence algorithms, and, in a structured way, it can pick up the tell-tale signs of the disease.

IQ-AI advances glioblastoma clinical trial, eyes phase two in 2025

Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring...

3 weeks, 4 days ago